DK174523B1 - Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis - Google Patents

Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis Download PDF

Info

Publication number
DK174523B1
DK174523B1 DK199100562A DK56291A DK174523B1 DK 174523 B1 DK174523 B1 DK 174523B1 DK 199100562 A DK199100562 A DK 199100562A DK 56291 A DK56291 A DK 56291A DK 174523 B1 DK174523 B1 DK 174523B1
Authority
DK
Denmark
Prior art keywords
cells
gamma interferon
smooth muscle
cell
expression
Prior art date
Application number
DK199100562A
Other languages
Danish (da)
English (en)
Other versions
DK56291D0 (da
DK56291A (da
Inventor
Goeran Hansson
Jan Holm
Lena Jonasson
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK56291D0 publication Critical patent/DK56291D0/da
Publication of DK56291A publication Critical patent/DK56291A/da
Application granted granted Critical
Publication of DK174523B1 publication Critical patent/DK174523B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
DK199100562A 1988-09-30 1991-03-27 Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis DK174523B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
SE8803472 1988-09-30
SE8900520 1989-09-27
PCT/SE1989/000520 WO1990003189A1 (en) 1988-09-30 1989-09-27 Use of gamma-interferon for the treatment of vascular stenosis

Publications (3)

Publication Number Publication Date
DK56291D0 DK56291D0 (da) 1991-03-27
DK56291A DK56291A (da) 1991-05-24
DK174523B1 true DK174523B1 (da) 2003-05-12

Family

ID=20373494

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199100562A DK174523B1 (da) 1988-09-30 1991-03-27 Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis

Country Status (18)

Country Link
US (1) US5208019A (de)
EP (1) EP0367735B1 (de)
JP (1) JP2895896B2 (de)
KR (1) KR0137017B1 (de)
AT (1) ATE86869T1 (de)
AU (1) AU623181B2 (de)
CA (1) CA1338722C (de)
DD (1) DD288094A5 (de)
DE (1) DE68905438T2 (de)
DK (1) DK174523B1 (de)
HU (1) HU206988B (de)
IE (1) IE63874B1 (de)
IL (1) IL91796A (de)
NZ (1) NZ230816A (de)
PH (1) PH26293A (de)
PT (1) PT91863B (de)
SE (1) SE462364B (de)
WO (1) WO1990003189A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1993015609A1 (en) * 1992-02-05 1993-08-19 Thomas Jefferson University Interferon gene therapy for the treatment of vascular disorders
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
DE69429087T2 (de) * 1993-01-07 2002-07-11 Thomas Jefferson University Ph Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
CA2210622A1 (en) * 1995-11-17 1997-05-29 Toray Industries, Inc. An agent protecting endothelial cells
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
WO1999051260A2 (en) 1998-04-02 1999-10-14 Genentech, Inc. Treatment of cardiac hypertrophy
US7524826B2 (en) * 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
WO2002089828A2 (en) * 2001-05-04 2002-11-14 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071357B1 (de) * 1981-07-14 1985-01-02 Efamol Limited Pharmazeutische und diätetische Zusammensetzung zur Erhöhung der Serie-l-Pg-Produktion
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4454115A (en) * 1981-10-23 1984-06-12 Wisconsin Alumni Research Foundation Method of reducing the level of low density lipoproteins in the serum of a patient
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
PT91863B (pt) 1995-05-31
KR900701308A (ko) 1990-12-01
KR0137017B1 (ko) 1998-04-25
WO1990003189A1 (en) 1990-04-05
DK56291D0 (da) 1991-03-27
AU4305189A (en) 1990-04-18
IL91796A (en) 1994-10-07
IL91796A0 (en) 1990-06-10
SE8803472D0 (sv) 1988-09-30
DE68905438T2 (de) 1993-09-30
CA1338722C (en) 1996-11-19
EP0367735B1 (de) 1993-03-17
EP0367735A1 (de) 1990-05-09
IE63874B1 (en) 1995-06-14
AU623181B2 (en) 1992-05-07
DD288094A5 (de) 1991-03-21
IE893123L (en) 1990-03-30
JP2895896B2 (ja) 1999-05-24
ATE86869T1 (de) 1993-04-15
DE68905438D1 (de) 1993-04-22
JPH04500966A (ja) 1992-02-20
HUT57063A (en) 1991-11-28
DK56291A (da) 1991-05-24
SE462364B (sv) 1990-06-18
NZ230816A (en) 1997-06-24
PH26293A (en) 1992-04-10
US5208019A (en) 1993-05-04
PT91863A (pt) 1990-03-30
HU206988B (en) 1993-03-01
HU895542D0 (en) 1991-10-28

Similar Documents

Publication Publication Date Title
DK174523B1 (da) Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis
Hansson et al. Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro.
Dietrich et al. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations
US5318957A (en) Method of stimulating angiogenesis
Dall'Amico et al. Successful treatment of recurrent rejection in renal transplant patients with photopheresis.
Fiedler et al. Octreotide treatment in patients with necrotizing pancreatitis and pulmonary failure
EP1358888A1 (de) Das humane Peptidantibiotikum LL-37/hCAP-18 ist ein Angiogeneseinduktor
CA2194485C (en) Endothelial lining effects and treatment of vasospastic disorders
EP0408677B1 (de) Steigerung der c1-inhibitorkonzentrationen mittels interferon gamma allein oder in kombination mit interleukin-6
US6060449A (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
EA035358B1 (ru) Способ, набор и комбинация для лечения субъекта с симптомами инсульта или острого инфаркта миокарда
CA2100876A1 (en) Anti-growth factor antibodies in the treatment of vascular stenosis
JP2002524420A (ja) 脈管形成に有効な単位用量のｆｇｆ−２および使用方法
EP1103269B1 (de) Verwendung von HGF für die Behandlung von ischämischen Erkrankungen der Extremitäten
Sun et al. Shuxuetong injection and its peptides enhance angiogenesis after hindlimb ischemia by activating the MYPT1/LIMK1/Cofilin pathway
JP2008007512A (ja) 動脈狭窄の減弱方法
JP2002529510A (ja) 哺乳動物においてアテローム性動脈硬化症を予防および退行させるための方法
US20100226911A1 (en) Treating or preventing extracellular matrix build-up
Kelley Rationale for hormone therapy in rheumatic fever
WO2017048157A1 (ru) Комбинаторная терапия для лечения геморрагического шока и последствий черепно-мозговой травмы
JPH09124506A (ja) 組織因子凝固系インヒビター含有動脈硬化治療剤
Khamidova et al. OCCURRENCE AND COURSE OF HYPERSPLENISM IN PATIENTS WITH CIRRHOSIS OF THE LIVER
Kadowaki et al. The effect of hypercholesterolemia on early atherosclerotic lesions initiated by fibrinopeptide B
Kokot et al. Low-dose aspirin and serum lipoprotein (a) concentrations in patients with EPH-gestosis
Li et al. The effect on vascular endothelial growth factor and C-reactive protein levels before and after coronary intervention treatment of coronary heart disease

Legal Events

Date Code Title Description
PUP Patent expired